Cargando…

Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign prostate hypertrophy, a proof of concept study in the spontaneously hypertensive rat supplemented with testosterone

BACKGROUND: The main purpose of this study is to investigate the effect of silodosin on the urodynamic consequences in a previously established model of lower urinary tract symptoms associated with benign prostate hyperplasia, the spontaneously hypertensive rats (SHR) supplemented with testosterone....

Descripción completa

Detalles Bibliográficos
Autores principales:	Assaly, Rana, Faugeroux, Julie, Laurin, Miguel, Compagnie, Sandrine, Alexandre, Laurent, Giuliano, François, Behr-Roussel, Delphine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453715/ https://www.ncbi.nlm.nih.gov/pubmed/32854676 http://dx.doi.org/10.1186/s12894-020-00699-y

Ejemplares similares

Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy
por: Karaca, Umut, et al.
Publicado: (2021)

Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously Hypertensive Rats Through Penile Tissue Remodeling and Neovascularization
por: Assaly, Rana, et al.
Publicado: (2019)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
por: Huynh Le Maux, Amélie, et al.
Publicado: (2015)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
por: Kim, Young Won, et al.
Publicado: (2015)

Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)

2108. Perfluorocarbon Omniphobic Treatment Prevents Bacterial Colonization of Urinary Catheter in a Rat Model
por: Badv, Maryam, et al.
Publicado: (2018)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

A Suspected Case of Silodosin-Induced Erythroderma
por: Liu, Annie, et al.
Publicado: (2015)

Silodosin-associated intraoperative floppy iris syndrome
por: Chatterjee, Samrat, et al.
Publicado: (2017)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial
por: Rahman, Md Jawaid, et al.
Publicado: (2017)

Use of Silodosin to Visualize the Posterior Urethra in Pelvic Floor Urethral Distraction Defect Patients
por: Ranjan, Nikhil, et al.
Publicado: (2015)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model
por: Behr-Roussel, Delphine, et al.
Publicado: (2016)

Testosterone deficiency reduces cardiac hypertrophy in a rat model of severe volume overload
por: Beaumont, Catherine, et al.
Publicado: (2019)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
por: Hagovska, Magdalena, et al.
Publicado: (2021)

Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study
por: Fusco, Ferdinando, et al.
Publicado: (2018)

The enhancing effects of testosterone in exposure treatment for social anxiety disorder: a randomized proof-of-concept trial
por: Hutschemaekers, Moniek H. M., et al.
Publicado: (2021)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Benign masseter muscle hypertrophy
por: Rispoli, Daniel Zeni, et al.
Publicado: (2015)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
por: Shimizu, Shogo, et al.
Publicado: (2015)

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review
por: Jindan, Luo, et al.
Publicado: (2022)

Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients
por: González-Álvarez, Isabel, et al.
Publicado: (2022)

Direct conversion from long‐acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept
por: Kavoussi, Parviz K., et al.
Publicado: (2022)

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies
por: Gittelman, Marc C, et al.
Publicado: (2010)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Cordyceps militaris Fruit Body Extract Decreases Testosterone Catabolism and Testosterone-Stimulated Prostate Hypertrophy
por: Kusama, Kazuya, et al.
Publicado: (2020)

Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study
por: Patil, Siddangouda B., et al.
Publicado: (2017)

Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone Supplements in Men
por: Dalmasso, Carolina, et al.
Publicado: (2017)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Silodosin vs tamsulosin in the management of distal ureteric stones: A prospective randomised study
por: Elgalaly, Hazem, et al.
Publicado: (2016)

The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis
por: Yang, Diandong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vphj9pe5umhg7f79a8osu5r11n